Loading...

Equillium

DB:0FY
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0FY
DB
$93M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Equillium has significant price volatility in the past 3 months.
0FY Share Price and Events
7 Day Returns
-17.7%
DB:0FY
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-
DB:0FY
-10.6%
DE Biotechs
-6.2%
DE Market
0FY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Equillium (0FY) -17.7% -25.3% - - - -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • No trading data on 0FY.
  • No trading data on 0FY.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

0FY Value

 Is Equillium undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Equillium. This is due to cash flow or dividend data being unavailable. The share price is €4.754.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Equillium's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Equillium's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0FY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.09
NasdaqGM:EQ Share Price ** NasdaqGM (2019-04-18) in USD $5.35
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Equillium.

DB:0FY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:EQ Share Price ÷ EPS (both in USD)

= 5.35 ÷ -1.09

-4.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Equillium is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Equillium is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Equillium's expected growth come at a high price?
Raw Data
DB:0FY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-16.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Equillium, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Equillium's assets?
Raw Data
DB:0FY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.74
NasdaqGM:EQ Share Price * NasdaqGM (2019-04-18) in USD $5.35
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:0FY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:EQ Share Price ÷ Book Value per Share (both in USD)

= 5.35 ÷ 3.74

1.43x

* Primary Listing of Equillium.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Equillium is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Equillium's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Equillium has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0FY Future Performance

 How is Equillium expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-16.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Equillium expected to grow at an attractive rate?
  • Unable to compare Equillium's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Equillium's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Equillium's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0FY Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0FY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -16.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0FY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0FY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 25 -25 -43 3
2022-12-31 4 -34 -49 3
2021-12-31 0 -24 -26 3
2020-12-31 0 -18 -42 3
2019-12-31 0 -13 -26 3
DB:0FY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -8 -13
2018-09-30 -4 -10
2017-12-31 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Equillium is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Equillium is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0FY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Equillium Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0FY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.68 -1.68 -1.68 1.00
2022-12-31 -2.31 -2.31 -2.31 1.00
2021-12-31 -1.26 -1.26 -1.26 1.00
2020-12-31 -1.82 -1.34 -2.30 2.00
2019-12-31 -1.49 -1.31 -1.67 2.00
DB:0FY Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.09
2018-09-30 -0.91
2017-12-31 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Equillium will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Equillium's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Equillium has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0FY Past Performance

  How has Equillium performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Equillium's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Equillium does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Equillium's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Equillium's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Equillium's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Equillium Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0FY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -13.25 3.67 4.94
2018-09-30 -9.82 2.20 3.17
2017-12-31 -2.71 0.45 1.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Equillium has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Equillium has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Equillium improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Equillium's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Equillium has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0FY Health

 How is Equillium's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Equillium's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Equillium is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Equillium's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Equillium's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Equillium has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Equillium Company Filings, last reported 3 months ago.

DB:0FY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 64.94 0.00 65.91
2018-09-30 -10.38 11.60 4.98
2017-12-31 -2.25 8.06 7.10
  • Equillium has no debt.
  • Equillium currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Equillium has sufficient cash runway for more than 3 years based on current free cash flow.
  • Equillium has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 149.3% each year.
X
Financial health checks
We assess Equillium's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Equillium has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0FY Dividends

 What is Equillium's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Equillium dividends.
If you bought €2,000 of Equillium shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Equillium's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Equillium's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0FY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0FY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Equillium has not reported any payouts.
  • Unable to verify if Equillium's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Equillium's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Equillium has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Equillium's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Equillium afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Equillium has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0FY Management

 What is the CEO of Equillium's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dan Bradbury
COMPENSATION $0
AGE 57
TENURE AS CEO 0.8 years
CEO Bio

Mr. Daniel Mark Bradbury, also known as Dan, serves as Chairman of the Board at DiaVacs, Inc. Mr. Bradbury serves as a Vice President of BIOCOM, Inc. He is a Co-Founder of Sensulin, LLC. Since May 2017, Mr. Bradbury has served as Chairman and Chief Executive Officer of Equillium, Inc., a private biopharmaceutical company that Mr. Bradbury co-founded. Mr. Bradbury has extensive experience in pharmaceutical industry strategy, operations and management. Mr. Bradbury is the founder of BioBrit, LLC and serves as its Managing Member since 2012. He is a life sciences executive with more than 30 years of experience in creating transformative business strategies, bringing novel medicines to market and maximizing shareholder value. Mr. Bradbury served as the President at Amylin Pharmaceuticals, LLC from June 2006 to March 2007 and served as its Chief Executive Officer from March 1, 2007 to August 2012, Chief Operating Officer from June 2003 to June 2006, Executive Vice President from June 2000 to June 2003, Senior Vice President of Corporate Development from April 1998 to June 2000 and Vice President of Marketing from June 1995 to April 1998. From July 1994 to May 1995, he served as Director of Marketing at Amylin Europe Limited. Prior to Amylin, Mr. Bradbury was employed at SmithKline Beecham Pharmaceuticals from September 1984 to July 1994, where he served a number of positions in international sales and marketing, including Associate Director, Anti-Infectives in the Worldwide Strategic Product Development Division. He served at SmithKline Beecham Limited. He serves as Chairman of the Board at Sensulin, LLC. He has been the Chairman of Liquid Grids, Inc. since May 13, 2014 and Freedom Meditech, Inc. since September 2014. He has been Chairman at Thesan Pharmaceuticals, Inc. since July 19, 2016. He has been Chairman of the Board at Castle Biosciences Incorporated since February 2015. He serves as the Chairman of Advisory Council at the Keck Graduate Institute of Applied Life Sciences. He has been a Director of Intercept Pharmaceuticals, Inc. since July 19, 2016. He served as Non-Executive Independent Director of Syngene International Ltd., from July 24, 2013 to May 15, 2016. He has been a Director at Renova Therapeutics Inc., since November 2014. He has been an Independent Director of Geron Corporation since September 26, 2012. He served as a Director of BioMed Realty Trust Inc., since January 4, 2013 until January 2016. He serves as a Director of Cerexa, Inc, DiaVacs, Inc., Sensulin, Inc., BIOCOM, Inc., Castle Biosciences Incorporated and Pharmaceutical Research and manufacturers of America (PhRMA) and served as Director at Microdermis Corporation (Microdermis, Inc.). He has been a Director at Peninsula Pharmaceuticals, Inc. since December 2003. He has been an Independent Director of Corcept Therapeutics Incorporated since October 15, 2012. He has been an Independent & Non-Executive Director of Biocon Limited since April 25, 2013. He has been a Director of Profil Institute for Clinical Research, Inc. since November 2013. He serves as a Member of Advisory Board at MD Revolution, Inc. He serves as a Member of Advisory Board of Investor Growth Capital and is responsible for biotechnology and pharmaceutical development. He served as an Independent Director of Novacea, Inc. since September 2005 and its Lead Director since December 2007. Mr. Bradbury served as a Director of Amylin Pharmaceuticals, LLC from June 2006 to August 2012. He serves as a Member of Business Advisory Board at AmideBio, LLC. He also serves as an advisory board member for the University of California San Diego. He serves as a Member of Advisory Council at The Rady School of Management at the University of California, San Diego. He served as an Independent Director of Illumina Inc. since January 9, 2004 until May 29, 2017. Mr. Bradbury is also a member of the board of trustees of the Keck Graduate Institute. He is a Member of RAND Health Board of Advisors and University of Miami's Innovation Corporate Advisory Council. He has been honored with the San Diego American Diabetes Association's Father of the Year Award (2011), the Corporate Directors Forum Director of the Year Award for Enhancing Economic Value (2012) and was Ernst & Young's Entrepreneur of the Year Finalist (2012). He is a member of the Royal Pharmaceutical Society of Great Britain. Mr. Bradbury completed the Director Certification Program at the University of California, Los Angeles (2004) and the International Executive Program from INSEAD, European Institute of Business Administration, France (1994). He holds a B. Pharm (Hons.) from Nottingham University, UK in the year 1980-1983 and a Postgraduate Diploma in Management Studies (DMS) and Diploma of the Chartered Institute of Marketing (DCIM) from Harrow and Ealing Colleges of Higher Education, UK in 1985.

CEO Compensation
  • Insufficient data for Dan to compare compensation growth.
  • Dan's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Equillium management team in years:

0.8
Average Tenure
47
Average Age
  • The average tenure for the Equillium management team is less than 2 years, this suggests a new team.
Management Team

Dan Bradbury

TITLE
CEO & Chairman
AGE
57
TENURE
0.8 yrs

Bruce Steel

TITLE
Co-Founder
AGE
52
TENURE
0.8 yrs

Stephen Connelly

TITLE
Chief Scientific Officer & Director
COMPENSATION
$30K
AGE
37
TENURE
1.3 yrs

Jason Keyes

TITLE
Chief Financial Officer
AGE
47
TENURE
1.1 yrs

Christine Zedelmayer

TITLE
Vice President of Operations

Krishna Polu

TITLE
Chief Medical Officer
AGE
45
TENURE
0.7 yrs

David Essayan

TITLE
Head of Regulatory Affairs

Tom Boone

TITLE
Head of CMC & Product Development
Board of Directors Tenure

Average tenure and age of the Equillium board of directors in years:

1.9
Average Tenure
57
Average Age
  • The average tenure for the Equillium board of directors is less than 3 years, this suggests a new board.
Board of Directors

Dan Bradbury

TITLE
CEO & Chairman
AGE
57
TENURE
2.1 yrs

Bruce Steel

TITLE
Co-Founder
AGE
52
TENURE
2.1 yrs

Stephen Connelly

TITLE
Chief Scientific Officer & Director
COMPENSATION
$30K
AGE
37
TENURE
2.1 yrs

Martha Demski

TITLE
Director
AGE
65
TENURE
0.6 yrs

Bala Manian

TITLE
Director
AGE
73
TENURE
1.9 yrs

Charlie McDermott

TITLE
Director
AGE
46
TENURE
0.6 yrs

Mark Pruzanski

TITLE
Director
AGE
50
TENURE
0.6 yrs

Vijay Kuchroo

TITLE
Member of Scientific Advisory Board
AGE
63

Fred Ramsdell

TITLE
Member of Scientific Advisory Board
AGE
57

Pradip Nair

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Equillium's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Equillium has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0FY News

Simply Wall St News

0FY Company Info

Description

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.

Details
Name: Equillium, Inc.
0FY
Exchange: DB
Founded: 2017
$82,662,577
17,376,236
Website: http://www.equilliumbio.com
Address: Equillium, Inc.
2223 Avenida De La Playa,
Suite 105,
San Diego,
California, 92037,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM EQ Common Stock Nasdaq Global Market US USD 12. Oct 2018
DB 0FY Common Stock Deutsche Boerse AG DE EUR 12. Oct 2018
Number of employees
Current staff
Staff numbers
11
Equillium employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:28
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/28
Last earnings filing: 2019/03/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.